Generic placeholder image

Current Alzheimer Research

Editor-in-Chief

ISSN (Print): 1567-2050
ISSN (Online): 1875-5828

Case Report

Primary Sjögren’s Syndrome Presenting with Rapidly Progressive Dementia: A Case Report

Author(s): Konstantinos Notas, Vasileios Papaliagkas*, Martha Spilioti, Ioannis Papagiannis, Petros Nemtsas, Athanasios Poulopoulos, Konstantinos Kouskouras, Ioannis Diakogiannis and Vasilios K. Kimiskidis

Volume 19, Issue 6, 2022

Published on: 18 July, 2022

Page: [479 - 484] Pages: 6

DOI: 10.2174/1567205019666220627094707

Price: $65

conference banner
Abstract

Background: Rapidly progressive dementias (RPDs) are dementias that progress subacutely over a time period of weeks to months. Primary Sjögren’s syndrome (pSS) is an autoimmune disease that can affect any organ system and may present with a wide range of clinical features that may mimic a plethora of medical conditions and, in rare cases, may manifest as RPD. We describe a unique case of pSS, in which rapidly progressive dementia (RPD) was the first disease manifestation, and the patient’s radiological and electroencephalogram findings were compatible with Creutzfeldt- Jakob disease (CJD).

Case Presentation: Here, we report a 58-year-old woman who presented with cognitive impairment rapidly deteriorating over the last 6 months prior to admission. Brain MRI and EEG were indicative of CJD. However, CSF 14-3-3 and tau/phospho tau ratio were within normal limits and therefore alternative diagnoses were considered. Blood tests were significant for positive antinuclear antibodies, anti-ENA, and anti-SSA and a lip biopsy was consistent with pSS. The patient was started on intravenous steroids followed by oral prednisone taper, which prevented further deterioration.

Conclusion: This rare case expands the spectrum of neurological manifestations in pSS and highlights the importance of considering pSS in the differential diagnosis of RPDs in order to avoid misdiagnosis and provide appropriate treatment in a timely fashion.

Keywords: Sjögren’s syndrome, creutzfeldt jakob disease, neurocognitive disorders, dementia, case report, autoimmune diseases of the nervous system, electroencephalography source imaging.

« Previous
[1]
Jin JO, Yu QT. Cell-associated cytokines in the pathogenesis of Sjögren's syndrome. J Clin Cell Immunol 2013; S(9): 11742.
[2]
Zerr I, Kallenberg K, Summers DM, et al. Updated clinical diagnostic criteria for sporadic Creutzfeldt-Jakob disease. Brain 2009; 132(Pt 10): 2659-68.
[3]
Shiboski CH, Shiboski SC, Seror R, et al. American college of Rheumatology/European league against rheumatism classification criteria for primary Sjögren’s syndrome: A consensus and data-driven methodology involving three international patient cohorts. Arthritis Rheumatol 2017; 69(1): 35-45.
[4]
Geschwind MD. Rapidly progressive dementia. Continuum (Minneapolis, Minn) 2016; 22(2 Dementia): 510-37.
[5]
Zerr I, Pocchiari M, Collins S, et al. Analysis of EEG and CSF 14-3-3 proteins as aids to the diagnosis of Creutzfeldt-Jakob disease. Neurology 2000; 55(6): 811-5.
[6]
Wieser HG, Schindler K, Zumsteg D. EEG in Creutzfeldt-Jakob disease. Clin Neurophysiol 2006; 117(5): 935-51.
[7]
Muayqil T, Gronseth G, Camicioli R. Evidence-based guideline: Diagnostic accuracy of CSF 14-3-3 protein in sporadic Creutzfeldt-Jakob disease: Report of the guideline development subcommittee of the American Academy of Neurology. Neurology 2012; 79(14): 1499-506.
[8]
Young GS, Geschwind MD, Fischbein NJ, et al. Diffusion-weighted and fluid-attenuated inversion recovery imaging in Creutzfeldt-Jakob disease: High sensitivity and specificity for diagnosis. AJNR Am J Neuroradiol 2005; 26(6): 1551-62.
[9]
Meissner B, Kallenberg K, Sanchez-Juan P, et al. MRI lesion profiles in sporadic Creutzfeldt-Jakob disease. Neurology 2009; 72(23): 1994-2001.
[10]
Atarashi R, Satoh K, Sano K, et al. Ultrasensitive human prion detection in cerebrospinal fluid by real-time quaking-induced conversion. Nat Med 2011; 17(2): 175-8.
[11]
Margaretten M. Neurologic Manifestations of Primary Sjögren Syndrome. Rheum Dis Clin North Am 2017; 43(4): 519-29.
[12]
Delalande S, de Seze J, Fauchais AL, et al. Neurologic manifestations in primary Sjogren syndrome: A study of 82 patients. Medicine (Baltimore) 2004; 83(5): 280-91.
[13]
Carvajal Alegria G, Guellec D, Mariette X, et al. Epidemiology of neurological manifestations in Sjogren’s syndrome: Data from the French ASSESS Cohort. RMD Open 2016; 2(1): e000179.
[14]
Massara A, Bonazza S, Castellino G, et al. Central nervous system involvement in Sjögren’s syndrome: Unusual, but not unremarkable--clinical, serological characteristics and outcomes in a large cohort of Italian patients. Rheumatology (Oxford) 2010; 49(8): 1540-9.
[15]
Morreale M, Marchione P, Giacomini P, et al. Neurological involvement in primary Sjögren syndrome: A focus on central nervous system. PLoS One 2014; 9(1): e84605.
[16]
Moreira I, Teixeira F, Martins Silva A, Vasconcelos C, Farinha F, Santos E. Frequent involvement of central nervous system in primary Sjögren syndrome. Rheumatol Int 2015; 35(2): 289-94.
[17]
Matsuo K, Saburi M, Ishikawa H, et al. Sjögren syndrome presenting with encephalopathy mimicking Creutzfeldt-Jakob disease. J Neurol Sci 2013; 326(1-2): 100-3.
[18]
Bourahoui A, De Seze J, Guttierez R, et al. CSF isoelectrofocusing in a large cohort of MS and other neurological diseases. Eur J Neurol 2004; 11(8): 525-9.
[19]
Pars K, Pul R, Schwenkenbecher P, et al. Cerebrospinal fluid findings in neurological diseases associated with Sjögren’s syndrome. Eur Neurol 2017; 77(1-2): 91-102.
[20]
Alexander EL, Lijewski JE, Jerdan MS, Alexander GE. Evidence of an immunopathogenic basis for central nervous system disease in primary Sjogren’s syndrome. Arthritis Rheum 1986; 29(10): 1223-31.
[21]
Alexander EL, Ranzenbach MR, Kumar AJ, et al. Anti-Ro(SS-A) autoantibodies in central nervous system disease associated with Sjogren’s syndrome (CNS-SS): Clinical, neuroimaging, and angiographic correlates. Neurology 1994; 44(5): 899-908.
[22]
Del Papa N, Vitali C. Management of primary Sjogren’s syndrome: Recent developments and new classification criteria. Ther Adv Musculoskelet Dis 2018; 10(2): 39-54.
[23]
Pascual-Marqui RD, Michel CM, Lehmann D. Low resolution electromagnetic tomography: A new method for localizing electrical activity in the brain. Int J Psychophysiol 1994; 18(1): 49-65.
[24]
Brunet D, Murray MM, Michel CM. Spatiotemporal analysis of multichannel EEG: CARTOOL. Comput Intell Neurosci 2011; 2011: 813870.
[25]
Nemtsas P, Birot G, Pittau F, et al. Source localization of ictal epileptic activity based on high-density scalp EEG data. Epilepsia 2017; 58(6): 1027-36.

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy